Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.

American journal of hematology - 1 Jun 2009

Ustun Celalettin, Jillella Anand P, Salama Mohamed E

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib
Share to Fusion Proteins, bcr-abl
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 19391130
DOI: 10.1002/ajh.21409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.PMID 19391130Read ↗

Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.Semantic proximity Read ↗

Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patientsSemantic proximity Read ↗

Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Semantic proximity Read ↗

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.Semantic proximity Read ↗

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.Semantic proximity Read ↗

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.Semantic proximity Read ↗

Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.Semantic proximity Read ↗

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.Semantic proximity Read ↗

Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.Semantic proximity Read ↗

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.Semantic proximity Read ↗

Cytogenetic and molecular mechanisms of resistance to imatinibSemantic proximity Read ↗

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.